| Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the … L Biganzoli, NML Battisti, H Wildiers, A McCartney, G Colloca, IH Kunkler, ... The Lancet Oncology 22 (7), e327-e340, 2021 | 160 | 2021 |
| Mechanisms of resistance to CDK4/6 inhibitors: potential implications and biomarkers for clinical practice A McCartney, I Migliaccio, M Bonechi, C Biagioni, D Romagnoli, ... Frontiers in oncology 9, 666, 2019 | 137 | 2019 |
| Metabolomics in breast cancer: A decade in review A McCartney, A Vignoli, L Biganzoli, R Love, L Tenori, C Luchinat, ... Cancer Treatment Reviews 67, 88-96, 2018 | 103 | 2018 |
| Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast … L Malorni, G Curigliano, AM Minisini, S Cinieri, CA Tondini, K D’hollander, ... Annals of Oncology 29 (8), 1748-1754, 2018 | 92 | 2018 |
| The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy I De Santo, A McCartney, I Migliaccio, A Di Leo, L Malorni Cancers 11 (12), 1894, 2019 | 61 | 2019 |
| Metabolomics to assess response to immune checkpoint inhibitors in patients with non-small-cell lung cancer V Ghini, L Laera, B Fantechi, F Del Monte, M Benelli, A McCartney, ... Cancers 12 (12), 3574, 2020 | 49 | 2020 |
| Plasma thymidine kinase activity as a biomarker in patients with luminal metastatic breast cancer treated with palbociclib within the TREnd trial A McCartney, M Bonechi, F De Luca, C Biagioni, G Curigliano, E Moretti, ... Clinical cancer research 26 (9), 2131-2139, 2020 | 43 | 2020 |
| Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor–positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of … A McCartney, C Biagioni, G Schiavon, M Bergqvist, K Mattsson, ... European Journal of Cancer 114, 55-66, 2019 | 35 | 2019 |
| COVID‐19 vaccination rates, intent, and hesitancy in patients with solid organ and blood cancers: A multicenter study M Nguyen, N Bain, L Grech, T Choi, S Harris, H Chau, D Freeman, ... Asia‐Pacific Journal of Clinical Oncology 18 (6), 570-577, 2022 | 28 | 2022 |
| Precision oncology via NMR-based metabolomics: A review on breast cancer A Vignoli, E Risi, A McCartney, I Migliaccio, E Moretti, L Malorni, ... International Journal of Molecular Sciences 22 (9), 4687, 2021 | 27 | 2021 |
| CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer I Migliaccio, M Bonechi, A McCartney, C Guarducci, M Benelli, L Biganzoli, ... Cancer Treatment Reviews 93, 102136, 2021 | 27 | 2021 |
| The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: a concise review L Rossi, A McCartney, I De Santo, E Risi, E Moretti, L Malorni, L Biganzoli, ... Cancer Treatment Reviews 74, 29-34, 2019 | 25 | 2019 |
| Serious underlying medical conditions and COVID-19 vaccine hesitancy: a large cross-sectional analysis from Australia D Day, L Grech, M Nguyen, N Bain, A Kwok, S Harris, H Chau, B Chan, ... Vaccines 10 (6), 851, 2022 | 23 | 2022 |
| The role of abemaciclib in treatment of advanced breast cancer A McCartney, E Moretti, G Sanna, M Pestrin, E Risi, L Malorni, L Biganzoli, ... Therapeutic Advances in Medical Oncology 10, 1758835918776925, 2018 | 23 | 2018 |
| Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical … SA Hurvitz, H Park, S Frentzas, CM Shannon, K Cuff, RW Eek, GT Budd, ... Journal of Clinical Oncology 39 (15_suppl), 1038-1038, 2021 | 22 | 2021 |
| A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients E Risi, A Grilli, I Migliaccio, C Biagioni, A McCartney, C Guarducci, ... Breast cancer research and treatment 170, 329-341, 2018 | 21 | 2018 |
| Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial F Galardi, F De Luca, C Biagioni, I Migliaccio, G Curigliano, AM Minisini, ... Breast Cancer Research 23, 1-12, 2021 | 19 | 2021 |
| Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled … L Rossi, C Biagioni, A McCartney, I Migliaccio, G Curigliano, G Sanna, ... Breast Cancer Research 21, 1-7, 2019 | 18 | 2019 |
| A serum metabolomics classifier derived from elderly patients with metastatic colorectal cancer predicts relapse in the adjuvant setting S Di Donato, A Vignoli, C Biagioni, L Malorni, E Mori, L Tenori, V Calamai, ... Cancers 13 (11), 2762, 2021 | 13 | 2021 |
| Cyclin-dependent kinase 4/6 inhibitors in neoadjuvant endocrine therapy of hormone receptor-positive breast cancer L Rossi, A McCartney, E Risi, I De Santo, I Migliaccio, L Malorni, ... Clinical breast cancer 19 (6), 392-398, 2019 | 12 | 2019 |
Angelo Di LeoHospital of PratoEmail verificata su uslcentro.toscana.it
